Canberra, Australia,, March 24, 2025 / Prnewswire / – Volpara Health, a world leader in mammary health solutions powered by AI and a subsidiary of Lunit, announced today two major stages:
- Volpara’s density is now a validated entry to the Boadicea breast cancer risk model.
- A record of 21 independent summaries featuring Lunit and Volpara solutions was presented at ECR 2025.
Volpara density now integrated into the Boadicea breast cancer risk model
The volumetric evaluation of Volpara breast density is now a validated entry to the newly published version of the Boadicea breast cancer risk model. This marks an important step, because Volpara’s density is now integrated into two different risk of breast cancer models – Tyrer -Cuzick and Boadicea, sometimes called Ibis or Canrisk, respectively.
All Volpara customers can use their Volpara density information via CANRISK today. Canrisk is approved by international companies and the guidelines to be used AustraliaEU, the United Kingdom, the United States and Canada. Studies have shown the use of Volpara density in Boadicea to improve the accuracy of the model in relation to the use of bi-rad density categories, improving the risk assessment capacities for breast cancer for health care providers worldwide.
A record of 21 Lunit and Volpara search summaries at ECR 2025
At the European Radiology Congress (ECR) 2025, Lunit and Volpara solutions were presented in a record of 21 independent research summaries. This step highlights the growing impact of mammary health solutions focused on AI in the global radiology community, strengthening Volpara’s commitment and is increasing to advance cancer detection and patient care thanks to innovation and scientific research.
About Volpara Health
Volpara Health’s mission is to save cancer families with software fueled by AI that helps health care providers to better understand the risk of cancer, guide personalized care decisions and recommend additional images and interventions. Used in more than 3,500 installations by more than 9,500 technologists worldwide. Volpara software has almost an impact 18m patients, support 3.6 m Annual risk assessments of cancer and fits perfectly with electronic health files and imaging systems. Volpara helps radiologists quantify dense mammary tissue with precision and technologists produce mammograms with positioning, compression and an optimal dose. Volpara software also rations operations to facilitate compliance and accreditation. Volpara, a company Lunit, has its headquarters Wellington, New Zealandand has an office in Seattle. Volpara is the trusted partner of the main health care institutions worldwide. For more information, visit www.volparahealth.com.
Volpara Media Contact:
Andrew Thompson-Young
Quest for clarity
(Protected by e-mail)
615-784-3103
Logo – https://mma.prnewswire.com/media/389465/volpara_health_logo.jpg
Volpara Health Source
